Baqsimi ® (glukagon näspulver)

För fullständig produktresumé för Baqsimi® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Baqsimi® (glukagon näspulver): Farmakodynamik hos vuxna

Efter administrering av glukagon näspulver till vuxna var den genomsnittliga maximala blodsockerhöjningen från baslinje 140 mg/dl.

Detailed Information

After administration of 3 mg NG in adult patients with type 1 diabetes, glucose levels began to rise as early as 5 minutes. By 10 minutes, the median glucose level was above 3.9 mmol/L (70 mg/dL). The mean maximum glucose increase was 7.8 mmol/L (140 mg/dL).1

Glucose Raising Effect in Study 1

Both NG and IM glucagon elicited a similar BG-raising effect (Figure 1).2

Figure 1. Mean Blood Glucose Concentrations After Administration of NG and IM Glucagon2

Abbreviations: IM = intramuscular; IMG = intramuscular glucagon; NG = nasal glucagon (glucagon nasal powder).

Other Parameters

Gender and body weight had no clinically meaningful effect on the pharmacodynamics of NG.1

Common cold with nasal congestion with or without concomitant use of a decongestant did not impact pharmacodynamics of NG.1

References

1. Baqsimi [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Suico J, Hovelmann U, Zhang S, et al. Nasal glucagon: a viable alternative to treat insulin-induced hypoglycemia in adults with type 1 diabetes. Talk presented at: Proceedings from the European Association for the Study of Diabetes; October 1-5, 2018; Berlin.

Glossary

BG = blood glucose

NG = nasal glucagon (glucagon nasal powder)

PD = pharmacodynamic

Datum fӧr senaste ӧversyn 2019 M07 24


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss